Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events : A Secondary Analysis of the PEGASUS-TIMI 54 Trial
Authors | |
---|---|
Year of publication | 2016 |
Type | Article in Periodical |
Magazine / Source | JAMA Cardiology |
MU Faculty or unit | |
Citation | |
Web | https://jamanetwork.com/journals/jamacardiology/fullarticle/2528235 |
Doi | http://dx.doi.org/10.1001/jamacardio.2016.1017 |
Field | Cardiovascular diseases incl. cardiosurgery |
Keywords | Ticagrelor; DUAL ANTIPLATELET THERAPY; MYOCARDIAL-INFARCTION; CLOPIDOGREL; ASPIRIN |
Description | In the PEGASUS-TIMI 54 trial, treatment with ticagrelor reduced the incidence of cardiovascular death,myocardial infarction, or stroke by 15%to 16%among stable patients compared with placebo. However, more patients prematurely discontinued treatment with ticagrelor than with placebo. |